Semaglutide
Semaglutide is a lab-made copy of GLP-1, a gut hormone that helps the body manage hunger and blood sugar. It is among the most heavily studied weight-loss and diabetes medicines, with trial programmes covering more than 45,000 participants.
At a glance
- Metabolic support
- subcutaneous, oral
- Not yet audited here; the reference library calls it emerging
- 2.4 mg per Peptide Dosing Protocols. See the source
- 5 mg in 2 mL
How much to draw
Full calculator →Opened on 2.4 mg, the figure Peptide Dosing Protocols reports for Semaglutide, and a 5 mg vial in 2 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Semaglutide or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 2.4 mg · Low: 0.25 mg · High: 2.4 mg | once weekly16 weeks · 16 weeks on, ongoing weekly maintenance | subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHideHalf-life: about 7 days. Standard dosing escalates to 2.4 mg over 16 weeks. |
- once weekly16 weeks · 16 weeks on, ongoing weekly maintenance
- subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
Half-life: about 7 days. Standard dosing escalates to 2.4 mg over 16 weeks.
- reconstituted lyophilized vial
We have not published an audit on Semaglutide. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Semaglutide switches on a single target, the GLP-1 receptor, which sits on cells in several organs, so it affects hunger, blood sugar, the stomach and the heart at once. Researchers attribute its long action to a change in the peptide chain that blocks the DPP-4 enzyme and a fatty acid chain that binds it to albumin, giving a half-life of about seven days. In the pancreas it triggers insulin release only when blood sugar is already high, which makes dangerously low blood sugar less likely than with some older diabetes drugs.
Semaglutide is a GLP-1 receptor agonist that copies a natural gut hormone (GLP-1) that helps the body manage hunger and blood sugar. [Source: Peptide Dosing Protocols]
Reported side effects
Seen in studies: in pooled STEP data at the higher weight-management dose, nausea occurred in 43.9 percent of participants against 16.1 percent on placebo, diarrhoea in 29.7 against 15.9 percent, vomiting in 24.5 against 6.3 percent and constipation in 24.2 against 11.1 percent. These clustered in the first 16 to 20 weeks and largely passed, with 99.5 percent of gut events non-serious. Resting heart rate rose by about 1 to 4 beats per minute, while one large trial showed a 20 percent drop in major heart events in people with obesity and existing heart disease. Gallstones were more common than on placebo, about 2.6 against 1.2 percent, in line with rapid weight loss generally, and pancreatitis was rare but reported. In SUSTAIN-6, retinopathy complications were higher than placebo, 3.0 against 1.8 percent, most likely from fast blood sugar improvement in people who already had it. In STEP, 6.8 percent stopped because of side effects against 3.2 percent on placebo.
Not ruled out: semaglutide carries a boxed warning based on thyroid C-cell tumours seen in rodent studies, and whether that applies to people is unknown.
Who should avoid it
People with a personal or family history of medullary thyroid carcinoma: contraindicated because of the boxed warning based on thyroid C-cell tumours in rodent studies.
People with multiple endocrine neoplasia type 2: contraindicated for the same reason.
People with known hypersensitivity to semaglutide or any ingredient in the formulation: contraindicated.
People who are pregnant or breastfeeding: it is not approved in pregnancy, and the label advises stopping well before a planned pregnancy because the drug stays in the body a long time.
People with a history of pancreatitis: pancreatitis has been reported in clinical trials.
People with existing diabetic retinopathy: complications were higher than on placebo in SUSTAIN-6, likely tied to fast blood sugar improvement.
People with gallbladder disease: gallstones were more common than on placebo in the STEP trials.
People with severe gut disease such as gastroparesis: semaglutide already slows stomach emptying, which would compound it.
What gets monitored
Body weight and HbA1c at weeks 1-4, 5-8, 8-12, 16-20, 28, and 68. (reported by Peptide Dosing Protocols)
Common questions
What amounts of semaglutide are used?
Reported amounts and schedules for semaglutide differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
What is semaglutide's half-life?
Semaglutide has a half-life of about seven days, which is the stated reason a weekly injection is enough. Steady blood levels take roughly four to five weeks to settle.
How much weight can you lose on semaglutide?
In the STEP 1 trial, participants on the higher weight-management dose lost an average of 14.9 percent of body weight at 68 weeks. In the SUSTAIN diabetes trials, semaglutide cut HbA1c by 1.5 to 1.9 percent.
How do you reconstitute semaglutide?
That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.
Is semaglutide FDA-approved?
Yes. As of June 2026, semaglutide has broad FDA approval across several indications, studied in programmes covering weight loss, diabetes, cardiovascular protection, kidney protection and fatty liver disease.
What are the most common side effects?
Stomach and bowel effects are the most common: nausea, diarrhoea, vomiting and constipation. They are usually worst in the first few months while the amount is being raised and tend to improve with time.
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
Cagrilintide / Retatrutide is a combination of cagrilintide, an amylin analog, and retatrutide, a triple GLP-1, GIP and glucagon agonist, sold pre-blended in one vial or as separate vials. It is discussed for weight management, and no clinical trial has tested the two together.
Cagrilintide / Tirzepatide is a combination of cagrilintide, an amylin analog, and tirzepatide, a dual GIP and GLP-1 agonist, each given once weekly from its own vial. It is discussed for weight management, with one study in obese rats and no human trial of the two together.
CagriSema is an investigational fixed-dose combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist, given once weekly. It has been studied for weight management in people in Phase 3 trials and is not FDA-approved as of June 2026.
Mazdutide, also called IBI362, is an investigational lab-made peptide drug that switches on two metabolic hormone receptors at once. It is being studied in clinical trials as a once-weekly injection for weight management and metabolic health.
Retatrutide is an investigational once-weekly injectable that acts on three hormone receptors at once: GLP-1, GIP and glucagon. It is being studied for weight and metabolic outcomes in adults with obesity, type 2 diabetes and fatty liver disease.
Tirzepatide is a lab-made peptide that switches on two gut-hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). It is studied in people for weight management and blood sugar control, including in the SURPASS and SURMOUNT trial programs.